Overview

Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria

Status:
Recruiting

Trial end date:
2024-02-15

Target enrollment:

Participant gender:

Summary

This study aims to determine the efficacy, safety and tolerability of the investigational drug KAF156 in combination with a solid dispersion formulation of lumefantrine (LUM-SDF) in pediatric patients (6 months to < 18 years of age) with uncomplicated P. falciparum malaria. There is an unmet medical need for anti-malarial treatment with a new mechanism of action to reduce the probability of developing resistance, and for a duration shorter than 3 days of treatment and/or reduced pill burden.

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals

Collaborator:

European and Developing Countries Clinical Trials Partnership (EDCTP)

Treatments:

Lumefantrine